These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17636117)

  • 21. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
    Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
    Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis.
    Damiano V; Rosa R; Formisano L; Nappi L; Gelardi T; Marciano R; Cozzolino I; Troncone G; Agrawal S; Veneziani BM; De Placido S; Bianco R; Tortora G
    Br J Cancer; 2013 Apr; 108(8):1616-23. PubMed ID: 23571736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
    du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
    Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Sweep FC; Geurts-Moespot A; Engelhardt MS; van der Graaf WT; Oyen WJ; van Laarhoven HW
    Mol Pharm; 2014 Nov; 11(11):4249-57. PubMed ID: 25294389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
    Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
    Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.
    Bruheim S; Sandvold ML; Mælandsmo GM; Fodstad O
    Anticancer Res; 2013 Sep; 33(9):3615-21. PubMed ID: 24023287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
    Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
    Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Fontanini G; Melisi D; Veneziani BM; Zunino F; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Dec; 7(12):4156-63. PubMed ID: 11751516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of endothelial cell network formation in vitro by molecular signaling of head and neck squamous cell carcinoma (HNSCC) exposed to cetuximab.
    Jouan-Hureaux V; Boura C; Merlin JL; Faivre B
    Microvasc Res; 2012 Mar; 83(2):131-7. PubMed ID: 21820450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
    Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
    Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.